Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866283 | 0.99 | APP (0.31) | APP | |
| SCHEMBL5920246 | 0.85 | CYP2D6 (0.36) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5920243 | 0.85 | CYP2D6 (0.36) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5920494 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5920489 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5920167 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5676936 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5677398 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5920165 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 | |
| SCHEMBL5920507 | 0.84 | CYP2D6 (0.35) | APPFFAR1PLA2G2APLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | APP 482/4885FFAR1 1944/4885PLA2G2A 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.